Neues Verfahren der Prostatabiopsie in der Urologie des Uni-Klinikums Erlangen
Der Urologe. Mess- bzw. Benign prostatic hyperplasia BPH is one of the Prostatatumor Urologie common urinary disorders in elderly men. The symptoms of this disease are increased prostate size, bladder outlet obstruction and lower urinary tract disorders. It influences bladder infections, bladder stone formation and increases the risk of urinary retention which can cause renal failure. It Prostatatumor Urologie necessary Prostatatumor Urologie the disease to be treated operatively.
The number of conducted surgical interventions for pharmacotherapy has been significantly reduced in recent years due to increased efficacy in conservative therapy including Prostatatumor Urologie treatment mostly with two groups of drugs: finasteride and alpha-blockers with different pharmacological activities.
The aim of the study was Prostatatumor Urologie evaluate finasteride efficacy in the treatment of benign prostatic hyperplasia. The clinical trial was conducted from October to November A total of 4, patients participated in the clinical trial and were enrolled in 50 urological centres in Poland.
The average age of the patients was The use of finasteride at least for 2 weeks was the criterion for the patient to be included in the study. The medical trial lasted 12 months and consisted of 6 visits at which data relating to IPSS, QoL, intensification of urinary system symptoms, the results of the additional studies, PSA serum concentrations, the urinary tract USG with evaluation of residual urine and prostate, urine analysis with evaluation of crystalline, uroflowmetry, Prostatatumor Urologie ultrasonography TRUS and biopsy were recorded.
The study did not exclude the Prostatatumor Urologie treatment with finasteride and alpha-adrenergic blocking drugs. Prostatocystitis was diagnosed in 30 men among the patients treated Prostatatumor Urologie the first visit after the digital rectal examination DRE trial and they qualified for antibiotic therapy.
Prostatatumor Urologie of a tumor was diagnosed in 69 1. Therefore, 4, patients took part in the clinical trial. In the course of 12 months patients were excuded from the study for different reasons: cardiac infarct, apoplexy, resignation without reason and change of address. Prostate cancer was confirmed histopathologically in 50 1. When the medical trial was finished, patients 5. A total of 3, out of Prostatatumor Urologie, Skip to main content. Advertisement Hide. Finasterid in der Behandlung der benignen Prostatahyperplasie.
Authors Authors and affiliations T. Originalien First Online: 07 July Finasteride in the treatment of benign prostatic hyperplasia. Background Benign prostatic hyperplasia BPH is one of the most common urinary disorders in elderly men. Materials and Prostatatumor Urologie The clinical trial was conducted from October to November Results Prostatocystitis was diagnosed in 30 men among the patients treated Prostatatumor Urologie the first visit after the digital rectal examination DRE trial and they qualified for antibiotic therapy.
Prostatatumor Urologie is a preview of subscription content, log in to check access. Interessenkonflikt Keine Angaben. Czasopismo Aptekarskie 17 12 —48 Google Scholar. Lepor H Alpha blockers for the treatment of benign prostatic hyperplasia. Przegl Urol —18 Google Scholar. Przegl Urol 4 2 Google Scholar. Urol Pol —59 Google Scholar. Geriatria — Prostatatumor Urologie Scholar.
Dutkiewicz S Choroby Stercza. Geriatr Pol 1 3 —74 Google Scholar. Personalised recommendations. Cite article How to cite? ENW EndNote. Buy options.